Rapport Therapeutics (RAPP) Accounts Payables (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Accounts Payables data on file, last reported at $6.6 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $6.6 million, up 206.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.6 million (up 206.73% YoY), and the FY2025 annual result was $4.2 million, up 114.43% from the prior year.
• Accounts Payables improved to $6.6 million in Q1 2026 per RAPP's latest filing, from $4.2 million in the prior quarter.
• Over five years, Accounts Payables peaked at $6.6 million in Q1 2026 and troughed at $1.3 million in Q3 2024.
• A 4-year average of $3.0 million and a median of $2.5 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2026: Accounts Payables decreased 21.9% in 2024, then surged 206.73% in 2026.
• A 4-year view of Accounts Payables shows it stood at $2.5 million in 2023, then dropped by 21.9% to $2.0 million in 2024, then surged by 114.43% to $4.2 million in 2025, then soared by 56.59% to $6.6 million in 2026.
• Business Quant data shows RAPP's Accounts Payables at $6.6 million in Q1 2026, $4.2 million in Q4 2025, and $3.2 million in Q3 2025.